REDHILL BIOPHARMA LTD.

Analyst Reco. RedHill Biopharma Ltd.

Equities

RDHL

US7574682024

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-21 pm EDT			5-day change	1st Jan Change
0.4747 ^USD	+3.20%		+3.85%	-67.49%

May. 06	Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib	MT
May. 06	RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Redhill Biopharma Says Opaganib Cuts Mortality Rates by 70.2% in Severe COVID-19 Patients	22-02-07	MT
Ascendiant Capital Adjusts Price Target on Redhill Biopharma to $19 From $26, Maintains Buy Rating	21-12-27	MT
Ladenburg Thalmann Adjusts Redhill Biopharma's Price Target to $9 from $21, Maintains Buy Rating	21-12-01	MT
REDHILL BIOPHARMA : HC Wainwright Trims Redhill Biopharma's Price Target to $21 From $23, Keeps Buy Rating	21-09-15	MT
Redhill Biopharma : Shares Climb after Cantor Fitzgerald Initiates Coverage With Overweight Rating	21-08-31	MT
Today on Wall Street: US tech giants return to top spot	21-08-31
ANALYST RECOMMENDATIONS : AT&T, BancorpSouth Bank, CMO Group, Magnite, Textron...	21-08-31
REDHILL BIOPHARMA : Cantor Fitzgerald Starts Redhill Biopharma at Overweight With $22 Price Target	21-08-31	MT
REDHILL BIOPHARMA : WBB Securities Downgrades Redhill Biopharma to Buy Rating From Strong Buy	21-05-28	MT
REDHILL BIOPHARMA : HC Wainwright Starts Redhill Biopharma at Buy With $23 Price Target	21-05-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW